ARTICLE | Clinical News
Daprodustat: Ph III started
December 1, 2016 11:42 AM UTC
GlaxoSmithKline began the open-label, U.S. Phase III ASCEND-ND trial to compare oral daprodustat once daily vs. subcutaneous darbepoetin alfa in about 4,500 non-dialysis-dependent patients switching f...
BCIQ Company Profiles
BCIQ Target Profiles